Skip to main content
. 2016 Feb 21;18(8):1146–1156. doi: 10.1093/neuonc/now009

Fig. 2.

Fig. 2.

Efficacy endpoints: (A) Kaplan-Meier curve for overall survival; (B) Kaplan-Meier curve for progression-free survival (based on investigator review). Patients at risk denote the number of patients who were event-free at the beginning of the period.